Document is current
Any future updates will be listed below
-
Authors
Rodriguez-Mogeda, Carla
Koubiyr, Ismail
Prouskas, Stefanos E.
Georgallidou, Margarita
van der Pol, Susanne M. A.
Fernandez, Rosalia Franco
de Graaf, Yvon Galis
van der Werf, Ysbrand D.
Jonkman, Laura E.
Schenk, Geert J.
Barkhof, Frederik
Hulst, Hanneke E.
Witte, Maarten E.
Schoonheim, Menno M.
de Vries, Helga E.
-
Funding
Funding for this research was provided by:
Stichting MS Research (22-358fMS, 18-358fMS, 18-358fMS)
ZonMw (09150172010056)
- License Information
-
More Information
Article History
Received: 4 February 2025
Revised: 1 May 2025
Accepted: 13 May 2025
First Online: 28 May 2025
Declarations
:
: IK has received research grants from LabEx TRAIL (Translational Research and Advanced Imaging Laboratory) and ARSEP (Fondation pour l’Aide à la Recherche sur la Sclérose En Plaques). MS serves on the editorial boards of Neurology, Multiple Sclerosis Journal and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience and ZonMW and has served as a consultant for or received research support from Atara Biotherapeutics, Biogen, Celgene/Bristol Meyers Squibb, EIP, Sanofi, MedDay and Merck. FB is supported by the NIHR biomedical research centre at UCLH, and is in the steering committee or Data Safety Monitoring Board member for Biogen, Merck, Eisai and Prothena. FB is advisory board member for Combinostics, Scottish Brain Sciences, Alzheimer Europe and is consultant for Roche, Celltrion, Rewind Therapeutics, Merck, Bracco. FB is also in research agreements with ADDI, Merck, Biogen, GE Healthcare, Roche and co-founder and shareholder of Queen Square Analytics LTD. LJ receives active funding from the Alzheimer Association (AARG-22–974381), The Dutch Top Sector Life Sciences and Health (S-000438), The Netherlands Organization for Health Research and Development (09120012110015), and Imeka.
